Abstract Boron neutron capture therapy (BNCT) is based on the nuclear capture and fission reactions that occur when non-radioactive 10 B is irradiated with low energy thermal neutrons to produce a-particles ( 10 B[n,a] 7 Li). Carboranylporphyrins are a class of substituted porphyrins containing multiple carborane clusters. Three of these compounds, designated H 2 TBP, H 2 TCP, and H 2 DCP, have been evaluated in the present study. The goals were two-fold. First, to determine their biodistribution following intracerebral (i.c.)
Introduction
Boron neutron capture therapy is based on the nuclear capture and fission reactions that occur when non-radioactive boron-10 is irradiated with neutrons of the appropriate energy to yield high energy alpha particles ( 4 He) and recoiling lithium-7 ( 7 Li) nuclei. Since these particles have pathlengths of approximately one cell diameter, their lethality primarily is limited to boron containing cells. BNCT, therefore, can be regarded as both a biologically and a physically targeted type of radiation therapy. Its success is dependent upon the selective delivery of sufficient amounts of 10 B to cancer cells with only small amounts localized in the surrounding normal tissues. A wide variety of boron delivery agents have been synthesized [1] , but only two of these currently are being used in clinically. The first, which has been used primarily in Japan, is sodium borocaptate or BSH, and the second is a dihydroxyboryl derivative of phenylalanine referred to as boronophenylalanine or BPA [2] . The latter has been used in clinical trials in Japan, Europe and the United States, primarily for the treatment of high grade gliomas, and more recently for recurrent tumors of the head and neck region. Following i.v. administration of either BPA or BSH by i.v. infusion, the tumor site is irradiated with neutrons, the source of which is a nuclear reactor.
Several recent clinical studies on the treatment of patients with glioblastomas (GBM) by means of BNCT have reported encouraging results [3] [4] [5] [6] . Careful analysis of survival data from a study, carried out in Sweden [3] in which BPA was administered at a higher dose over a longer period of time [4] , suggested that a subset of patients had survival times that were at least as good as those obtained with conventional therapy consisting of X-irradiation in combination with temozolomide (TMZ) [7] . Similarly, BNCT studies carried out by Miyatake and Kawabata and their co-workers [5, 6] , in which BPA and BSH were administered in combination, followed by an X-ray boost [6] showed favorable responses in patients with newly diagnosed GBM and especially those in high risk groups [6] . However, a randomized Phase III clinical trial ultimately will be necessary to unequivocally establish that BNCT can produce equivalent or superior survival data compared to the current standard treatment of surgery followed by RT and TMZ. Interested readers are referred to the recently published proceedings of the Thirteenth International Congress on Neutron Capture Therapy for more detailed information relating to BNCT [8] .
There has been a long-standing interest on the part of a number of research groups on the design, synthesis and biological evaluation of boron-containing porphyrins as delivery agents for BNCT [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Detailed information on this subject is provided in two comprehensive reviews on boronated porphyrins [21, 22] . The carboranylporphyrins used in the present study belong to a class of meso-substituted porphyrins containing four nido-carborane clusters and 36 boron atoms per molecule (37-31% boron by weight), linked to the porphyrin macrocycle via hydrolytically-stable carbon-carbon bonds. These compounds have been designated 5,10,15,20-tetra-(4-nido-carboranylphenyl)tetrabenzoporphyrin (H 2 TBP), 5,10,15,20-tetra-(4-nido-carboranylphenyl)porphyrin (H 2 TCP) and 5,15-di-[3,5-(nido-carboranylmethyl)phenyl]porphyrin (H 2 DCP) and their structures are shown in Fig. 1 . The synthesis and preliminary biological evaluation of H 2 TCP [23] [24] [25] [26] , H 2 DCP [26, 27] and H 2 TBP [28, 29] , previously have been reported. Earlier studies [23] [24] [25] [27] [28] [29] suggested that H 2 TCP, H 2 DCP and H 2 TBP were promising boron delivery agents due to their low toxicity and enhanced tumor uptake.
Based on the reports of Ozawa et al. [30, 31] and our own experience with CED [32] , we decided to focus on direct i.c. delivery of the carboranylporphyrins rather than Fig. 1 Chemical structures of the carboranylporphyrins used in this study: A tetra(4-nido-carboranylphenyl)tetra-benzo-porphyrin, H 2 TBP; B tetra(4-nido-carboranylphenyl) porphyrin (H 2 TCP); and C di[3,5-(nido-carboranylmethyl)phenyl]porphyrin (H 2 DCP) systemic administration. CED is an innovative method for local drug delivery to brain tumors by which a pressure gradient, or bulk flow, is used to drive an infusate through the extracellular compartment [33] . It allows delivery of the infusate to the tumor and surrounding brain at much higher concentrations than could be achieved by systemic administration. As demonstrated in both animal studies [32, 34] and clinical trials [35, 36] , CED not only increased the delivery of both low and high molecular weight agents, but also improved their therapeutic efficacy. Initially, we carried out some preliminary studies with several carboranylporphyrins using the F98 rat glioma model [37] . We now present a more detailed evaluation of the biodistribution and efficacy of H 2 TCP, H 2 DCP and H 2 TBP as potential boron delivery agents for neutron capture therapy (NCT).
Materials and methods

Synthesis of carboranylporphyrins
All nido-carboranylporphyrins were synthesized from the corresponding closo-carboranylporphyrins via baseinduced degradation for H 2 TCP and H 2 DCP or fluorideinduced degradation for H 2 TBP [38] . Therefore, all of them were stereoisomers, as shown by 1 H-NMR spectra and ab initio calculations, which might contribute to their therapeutic efficacy. The percent boron by weight was 27% for H 2 TBP and 31% for H 2 TCP and H 2 DCP. Two of these were converted to their zinc complexes, ZnDCP and ZnTCP, for the biodistribution studies described below. These were all stable for months at physiologic temperatures, but they were light sensitive and, therefore, they were shielded from light prior to their administration.
Biodistribution of ZnDCP and ZnTCP in glioma bearing mice
Biodistribution studies were carried out in female C57Bl/6 mice (Animal Production Branch, National Cancer Institute, Frederick, MD), weighing 20-25 g, bearing the syngeneic murine GL261 glioma. This tumor was induced by the i.c. implantation of methylcholanthrene pellets into the brain of a C57Bl/6 mouse [39] . It is composed of poorly differentiated cells histopathologically consistent with a glioblastoma. Tumor cells were implanted subcutaneously (s.c.) into the right dorsum with an inoculum of 1.8 9 10 6 cells. Biodistribution studies were carried out 15 days after implantation at which time the tumor volumes were * 80 mm 3 . The zinc(II) complexes of H 2 DCP and H 2 TCP, ZnDCP and ZnTCP, respectively, were injected intraperitoneally (i.p.) over 8 h in three doses totaling 30 mg boron/kg body weight (b.w.). Since these compounds are photosensitizers, the animals were shielded from light during the course of the experiment. In order to compare their biodistribution with that of BPA, another group of mice received a single i.p. injection of BPA at a concentration of 500 mg/kg b.w. Mice were euthanized at 24 and 48 h following the first injection and tissue and blood samples were taken for boron determinations by means of direct current plasma-atomic emission spectroscopy (DCP-AES), as previously described by us [40] . All animal studies were done in accordance with the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, DC, 1996) and the protocol was approved by the Institutional Laboratory Animal Care and Use Committee of The Ohio State University.
F98 rat glioma model
The F98 rat glioma (#CRL-2397, American Type Culture Collection, Manasus, VA) was derived from an undifferentiated neoplasm transplacentally induced in the progeny of a pregnant CD Fischer rat by the i.v. administration of N-ethyl-N-nitrosourea [41] . It has been propagated in vitro and in vivo since 1971 and, as described in a recent review [42] , the F98 glioma has been used in a wide variety of studies in experimental neuro-oncology. This tumor has an infiltrative pattern of growth within the brain, and an i.c. inoculum of as few as ten cells can be fatal. In the present study, F98 cells were grown in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT), 100 units/ml penicillin, 100 lg/ml streptomycin and 2 mM L-glutamine. Fischer rats (Animal Production Branch, National Cancer Institute, Frederick, MD), weighing 220-240 g, were used in these studies. A stereotactic implantation procedure, which has been described in detail elsewhere, was employed [43] . Briefly, rats were sedated by i.p. administration of a 1.2:1 mixture of ketamine/xylazine at a dose of 120 mg of ketamine/20 mg xylazine/kg b.w. Following this, a small burr hole was drilled into the calvarium and a plastic screw with an entry port (Arrow Machine Manufacturing, Inc., Richmond, VA) was embedded into the skull. F98 cells at a concentration of either 10 3 for therapy studies or 10 5 cells for biodistribution studies were injected stereotactically into the right caudate nucleus over 10-15 s through a small entry port of the plastic screw. Following this, the entry port was filled with bone wax immediately after withdrawal of the needle, and the operative field was flushed with betadine before the scalp incision was closed with a single sterilized clip. Eleven to thirteen days after tumor implantation of 10 5 cells, when clinical signs of a progressively growing i.c. tumor were evident, biodistribution studies were initiated.
Biodistribution studies in F98 glioma bearing rats following convection-enhanced delivery (CED) of carboranylporphyrins Since the zinc(II) complexes of carboranylporphyrins had lower cellular uptake than the free base porphyrins, studies subsequently were carried out with H 2 DCP and H 2 TCP. In order to increase tumor uptake and decrease uptake by extracranial organs and tissues, these were administered i.c. by means of CED or Alzet TM pump infusion to F98 glioma bearing rats. Eleven to thirteen days after tumor implantation, when signs of a progressively growing i.c. tumor were evident (weight loss, lethargy, hunching, and ataxia), biodistribution studies were initiated. In contrast to the biodistribution studies carried out in mice, which had received the test porphyrins by i.p. injection, it was not necessary to shield these rats from light. For short term CED of the carboranylporphyrins, a 28 gauge needle was inserted into the entry port of the plastic screw and then advanced 5 mm below the dura into the tumor. The boronated porphyrins were diluted with phosphate buffered saline (PBS), pH 7.4, to yield a concentration of 0.1-0.2 mg of compound in 10 ll. They compounds were administered by CED at a flow rate of 0.33 ll/min for 30 min using a syringe pump (Harvard Apparatus Co, Cambridge, MA). Biodistribution was determined immediately after and 24 and 48 h after termination of CED. Animals were euthanized by an overdose of halothane, following which tumors and normal tissues, consisting of brain, blood, liver, kidney and muscle, were removed and weighed. Uptake of boron was quantified by means of DCP-AES [40] .
Biodistribution of carboranylporphyrins following i.c. infusion by osmotic pumps
Alzet osmotic pumps (model #2001 D) and brain infusion kits (rigid stainless-steel cannula, 7 mm, 28 gauge) were assembled and filled with 200 ll of the test carboranylporphyrins. The pumps were stored in the dark in a sterile solution of 0.9% saline at 37°C for 24 h prior to their use. Fourteen days after tumor implantation, the rats were anesthetized again and the scalp was reopened. The pumps were implanted s.c. between the scapulae. The infusion cannula and needle were inserted stereotactically into the entry port of the plastic screw and the needle was advanced 5 mm below the dura into the tumors of glioma bearing rats. H 2 DCP, H 2 TCP or H 2 TBP at varying doses, ranging from 0.2 to 1.0 mg, were delivered in volume of 200 ll at a constant flow rate of 8 ll/h over 24 h following which the animals were euthanized immediately (t = 0) or 24 or 48 h later. Boron concentrations were determined in samples of tumor, brain, blood, liver, spleen, kidneys, lungs and heart by means of DCP-AES.
Therapy experiments
BNCT was performed 14 days following stereotactic implantation of 10 3 F98 glioma cells. Rats were transported to the Nuclear Reactor Laboratory at the Massachusetts Institute of Technology (MIT). Based on the results of the biodistribution study, a total of either 0.2 mg of the compound was administered by CED for 30 min or 0.5 mg of the compound was infused for 24 h by Alzet pumps. The animals were then randomized on the basis of weight into experimental groups of 9-10 animals each as follows: Group 1, H 2 TCP, administered by Alzet pumps and BNCT; Group 2, H 2 TBP by Alzet pumps and BNCT; Group 3, H 2 TBC by CED and BNCT; Group 4, H 2 TBP by CED ? i.v. BPA and BNCT; Group 5, i.v. BPA, followed 2.5 h later by BNCT; Group 6, CED of saline and neutron irradiation; Group 7, unirradiated controls that received H 2 TCP by CED. BNCT was initiated 24 h after termination of CED or infusion and 2.5 h after i.v. administration of 10 B enriched BPA at a dose of 500 mg/kg b.w. (Ryscor Science, Inc., Raleigh, NC). All irradiated rats were anesthetized with a mixture of ketamine and xylazine. BNCT was carried out at the MITR-II nuclear reactor in the M011 irradiation facility. This produces a beam of thermal neutrons of high purity and intensity with no measurable fast neutron component. Two rats at a time were positioned in a 6 Li enriched polyethylene box that provided whole body shielding from the thermal neutrons during an irradiation. The animals' heads were aligned in the middle of a 13 9 2 cm 2 aperture, which served as the beam collimator. Four fission counters, located at the periphery of the 15 cm circular field automatically controlled beam delivery and provided real time data on the relative neutron fluence during an irradiation.
Dosimetry
After completion of BNCT, the animals were held at MIT for *3 days to allow induced radioactivity to decay before they were returned to The Ohio State University for clinical monitoring. Dosimetric measurements were performed using bare gold foils and a graphite walled ionization chamber (V = 0.1 cm 3 ) flushed with reagent grade CO 2 on both dead rats and phantoms made from type 6 nylon [44] . The measured dose rates in brain (2.2% nitrogen by weight), normalized to the reactor operating at a power of 5 MW, were 18.5 cGy/min for photons, 7.7 cGy/min for thermal neutrons from the nitrogen capture reaction and 3.4 cGy/min per lg 10 B in tissues. For dosimetric calculations, boron concentrations were determined in tumor, normal brain, liver and blood in a separate group of animals 24 h after CED of carboranylporphyrins and 2.5 h after i.v. injection of BPA. Animal irradiations were performed with the reactor operating at a power between 4.0 and 4.8 MW, and these took approximately 7 min to deliver a thermal neutron fluence of 2.64 9 10 12 n.cm -2 to complement previous dose prescriptions [45] .
Monitoring of clinical status and neuropathologic evaluation
All animals were weighed three times per week and their clinical status was evaluated at the same time. Once the animals had progressively growing tumors, as evidenced by the combination of sustained weight loss, ataxia and peri-orbital hemorrhage, they were euthanized in order to minimize discomfort. Survival times were determined by adding 1 day to the time between tumor implantation and euthanization. The brains of all animals in the therapy studies were removed after death, fixed in 10% buffered formalin, and then cut coronally at the level of the optic chiasm and 2 mm anterior and posterior to it. Tissue sections through the tumor were embedded in paraffin, cut at 4 lm, stained with hematoxylin and eosin (H&E), and examined microscopically to assess the histopathologic changes.
Statistical evaluation
The means and standard deviations (SD) were computed for boron concentrations in all the major organs of C57B1/ 6 mice bearing s.c. implants of the GL261 murine glioma, as described in Table 1 , and for the tumor, brain, and blood of the F98 glioma rats, as described in Table 2 . Tumor:-brain and tumor:blood boron concentration ratios were calculated for each group. To study the effects of BNCT on survival of F98 glioma bearing rats, the mean survival time (MST), SD, and median survival time (MeST) were calculated for each group using the Kaplan-Meier estimate [46] . Kaplan-Meier curves also were plotted for all groups. An overall log rank test was performed to test for equality of survival curves over the groups. Wald tests were used for individual comparisons between two groups, with a Bonferroni method of adjustment for multiple comparisons [47] . Since there was no censoring of the survival data, a two sample t test also was used to compare MSTs in order to increase the power of the test. The percent increased life span (% ILS) was determined from the following equation:
where ''t'' designates treated and ''u'' designates untreated animals.
Results
Biodistribution after systemic injection of carboranylporphyrins
Following i.p. injection of either ZnDCP or ZnTCP (30 mg B/kg b.w.) to GL261 tumor bearing mice, one of five animals in each group died within the first 24 h and the others demonstrated reduced activity, suggesting that these doses of the zinc complexes were toxic. In contrast, H 2 DCP and H 2 TCP previously were shown to have very low toxicity [27, 28] . The boron uptake in tumor and normal tissues at 24 and 48 h following the third i.p. injection are summarized in Table 1 . The tumor boron concentrations at 48 h were 7.6 ± 1.9 and 5.2 ± 0.3 lg/g of tissue for ZnDCP and ZnTCP, respectively, compared to 1.2 ± 0.4 and 0.5 ± 0.1 lg/g in normal brain. In contrast, the 48 h boron concentrations in the liver were 154.9 ± 28.4 and 46.3 ± 11.5 lg/g, respectively, and the spleen concentrations were 138.5 ± 60.1 and 114.0 ± 99.1 lg/g with marked animal to animal variability. This possibly reflected differences in the excretion of the compounds and their metabolites. The corresponding blood concentrations were 15.9 ± 3.5 and 11.3 ± 2.5 lg/ml, respectively. Based on these data, a decision was made to administer the carboranylporphyrins i.c. either by short term (30 min) CED or by a 24 h infusion using Alzet osmotic pumps. In contrast to the high extracranial tissue uptake of ZnDCP and ZnTCP, BPA had very low concentrations in all organs except for tumor (12.5 ± 4.1 lg/g).
Biodistribution following delivery of carboranylporphyrins by either CED or Alzet pumps
As shown in Tables 2 and 3 , administration by either Alzet pumps or CED resulted in higher tumor and lower normal tissue boron concentrations, and improved tumor:brain (T:Br) and tumor:blood (T:Bl) ratios compared to those obtained following i.p. injection (Table 1 ). The boron concentrations in tumor and selected normal tissues in F98 glioma bearing rats following Alzet pump delivery of H 2 TCP at doses of 0.2, 0.5 or 1.0 mg/200 ll, delivered i.c. into F98 glioma bearing rats are summarized in Table 2 . Tumor boron concentrations were clearly dose dependent immediately following infusion and at 24 and 48 h later. The highest tumor boron concentrations were observed at 24 h following administration of escalating doses of H 2 TCP (24.6, 102.9 and 149.6 lg/g), but these were all within 1 SD of the concentrations that were observed immediately following infusion, indicating that there was retention and possibly some accretion of boron within the tumor. In contrast, the tumor concentrations had fallen Li reactions d Based on the low tumor boron values and the calculated physical radiation doses, BNCT was not carried out using H 2 DCP quite precipitously by 48 h to values that were one-third of their peak value, while the normal brain and blood values were low at the three time points (0.2-3.3 lg/g) except for those animals that received the 1.0 mg dose. Their normal brain values were higher at 0, 24 and 48 h (6.5, 10.1 and 3.0 lg/g, respectively). Although the highest T:Br ratio was seen with the dose of 0.5 mg at 48 h after administration, the tumor boron concentration was low (16.8 lg/g). Therefore, the most favorable values of tumor boron (102.9 lg/g) and T:Br ratios for H 2 TCP were seen with this dose at 24 h. In contrast, the tumor boron values for H 2 TBP and H 2 DCP at the same time and dose were 61.9 ± 16.4 and 35.6 ± 9.0 lg/g, respectively ( Table 3 ). The highest tumor boron concentration was seen 24 h following short term (30 min) CED of H 2 TBP (140.3 ± 70.9 lg), but as indicated by the large SD, there was considerable animal to animal variability. It should be noted that the T:Br boron concentration ratios of the carboranylporphyrins were markedly increased over those that we have observed following either i.v. or intracarotid (i.c.) administration of BPA and BSH [43] .
Boron neutron capture therapy
The carboranylporphyrins were administered 14 days following tumor implantation and BNCT was carried out 24 h after termination of delivery. This was well tolerated and weight loss in the first week was less than 20%, following which the animals regained their weight. The estimated physical radiation doses delivered to tumor, brain and blood were calculated according to boron concentrations summarized in Table 3 . In contrast, following i.c. administration of the carboranylporphyrins no boron was detected in samples of liver, spleen, kidneys, lungs and heart (data not shown). The highest physical radiation doses delivered to the tumor were 34.0 Gy for H 2 TBP, administered by CED, and 25.4 Gy for H 2 TCP, administered by Alzet pumps. The corresponding normal brain doses were 1.9 and 2.5 Gy, respectively ( Table 3 ). The survival data following BNCT are summarized in Table 4 , and Kaplan-Meier survival plots are shown in Figs. 2, 3 and 4 . The MSTs were 35.0 ± 3.7 and 43.8 ± 10.0 days, respectively, for rats that received H 2 TCP and H 2 TBP by Alzet pump ( Table 4 ). Animals that received H 2 TBP by Alzet pumps had a significantly longer MST than those that received H 2 DCP (P \ 0.017). Further studies were carried out using H 2 TBP at a dose of 0.2 mg, administered by CED, either alone or in combination with i.v. BPA. The corresponding MSTs were 33.8 ± 3.1 and 42.8 ± 9.0 days, respectively (Table 4 and Fig. 3 ). As shown in Fig. 4 , there were more long term survivors among rats that received the combination of i.v. BPA and H 2 TBP, compared to those that received H 2 TBP alone (P \ 0.001). The animals that received of H 2 TBP by Alzet pump (Table 4 and Fig. 5 ) had longer MSTs than those that received it by CED (43.8 vs. 33.8 days), demonstrating that Alzet pump delivery was more effective than CED (P \ 0.013). If the MSTs of animals that received i.v. BPA are compared to those of rats received H 2 TBP by either CED or Alzet pump using a log-rank test, they were not significantly different from one another (P = 0.38 and 0.16, respectively). The highest %ILS (87.2%) was observed among those animals that received H 2 TBP by osmotic pumps and this was equivalent to the %ILS of animals that received H 2 TBP by CED and i.v. BPA (82.8%). Neuropathologic evaluation
The most notable histopathologic finding was the presence of porphyrin laden macrophages and extracellular deposits of porphyrins in the tumors of many of the rats that received either H 2 TCP or H 2 TBP by either CED or Alzet pump infusion ( Fig. 5A and B) . As shown in Fig. 5B , this material was bright orange in color and was easily discernible on H&E stained sections of the tumor. In most instances, the appearance of the tumor in both treated and untreated animals was similar to that previously described by us [39] . As previously described by one of us (RFB), the tumor was composed of cells that varied in size and shape from ovoid to fusiform, sometimes displaying a whorled pattern of growth [42] . [24, 48] who observed that the tumor boron concentrations following i.t. administration of H 2 TCP to C57B1/6 mice bearing s.c. implants of the B16 melanoma were 109 greater than those observed following i.v. injection (60 vs. 6 lg/g). However, following BNCT the tumor growth delay was practically identical for both groups. Although the tumor boron concentrations for the latter animals was not determined, published data would suggest that it could have been in the range of 10 lg/g [49] . Similarly, Shibata et al. [50] have reported a very modest increase in the MST of 9L gliosarcoma bearing rats that received a BSH-porphyrin compound designated STA-BX900 (16.2 vs. 14.8 days and 12.8 days for irradiated and untreated control animals, respectively). However, since the tumor boron concentrations were so much higher following either CED or infusion by Alzet pumps than those obtained with other boron compounds, it was puzzling why the survival data were similar to those obtained with BPA, which had a much lower tumor boron concentration. Histopathologic examination of brains from tumor bearing, BNCT treated rats revealed that in most animals there were large numbers of porphyrin containing macrophages ( Fig. 5A and B) indicating that in reality the tumor cell uptake was much lower than would have been predicted, based on the tumor boron values determined by DCP-AES. This provides an explanation as to why the survival data were similar to those obtained with BPA, despite the seemingly high ''tumor'' boron concentrations. One possible explanation for the high uptake of the carboranylporphyrins by macrophages and the relatively low uptake by tumor cells could be related to their propensity to form aggregates when high concentrations are solubilized in water. This problem could be obviated by initially dissolving them in dimethylsulfoxide (DMSO) and then diluting it down to 1% DMSO. Theoretically, bystander killing might occur if the 10 B containing macrophages were adjacent to tumor cells. However, the potential lethality of the alpha particles produced as a result of the 10 B(n,a) 7 Li capture reaction would be much less than if they were produced within the tumor cells. Although CED has been effective in improving the distribution of a variety of agents in rats with brain tumors, its effectiveness in humans has been much more problematic [35, 36] . However, as demonstrated in the present study, direct i.c. delivery of therapeutic agents, which bypass the BBB, results in much higher concentrations in the brain tumor and concomitantly lower concentrations in extracranial sites thereby reducing systemic toxicity.
Ozawa et al. [30, 31] , as well as we [37] , have observed that CED and Alzet pump infusion resulted in significantly higher tumor and lower normal brain boron concentrations than those obtained following systemic administration. They were the first to report that CED significantly increased the tumor uptake of two boronated porphyrins, designated TABP-1 and BOPP, although no BNCT studies were carried out. As shown by us in the present studies, although CED of the carboranylporphyrins has solved the problem of high extracranial tissue uptake by the liver and spleen, the seemingly high tumor boron values did not accurately reflect the true intracellular uptake of the compounds. Direct i.c. administration appears to be the preferred route of administration for the presently available carboranylporphyrins. However, increasing their intracellular localization and homogeneous distribution depend on their physico-chemical properties and mechanism of delivery, which could improve their therapeutic efficacy. Therefore, we currently are synthesizing compounds with enhanced tumor cell uptake. In addition, it would be highly advantageous to have tumor selective compounds that readily cross the BBB, and that could be administered systemically and attain high tumor and low normal brain and extracranial tissue concentrations. It is noteworthy that in vitro studies on the cellular uptake of H 2 TCP studies with the murine B16 melanoma [24, 48] cells and H 2 TBP with human T98 glioblastoma cells [28] demonstrated intracellular fluorescence of cells that had been incubated with these compounds. Despite their tetra-anionic nature, they were able to penetrate plasma membranes to a certain extent, and may not have formed aggregates, thereby producing intense cellular fluorescence.
Our data provide a cautionary note that high ''tumor'' boron concentrations do not necessarily mean that the boron delivery agent is localized within tumor cells. In the future, we plan to carry out studies using secondary ion mass spectrometry (SIMS) [51] to obtain quantitative data on the boron concentrations of individual tumor cells in tissue sections. This method has been used to determine the cellular and subcellular localization of BPA [52] , BSH [53] and carboranyl nucleosides [54] . The challenge will be synthesize and evaluate non-toxic carboranylporphyrins with improved water solubility, which attain high in vivo tumor cell uptake following either systemic injection or direct i.c. administration. Based on the studies of Ozawa et al. [30, 31] , Jori, et al. [48] and ourselves, it can be concluded that these compounds are a class of boron delivery agents that warrant further investigation.
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